J&J's pancreatic-enzyme treatment Pancreaze gains FDA approval

04/12/2010 | Reuters

The FDA approved Pancreaze for use in patients with cystic fibrosis and other conditions caused by pancreatic-enzyme deficiency. The treatment, developed by Johnson & Johnson, will compete with pancreatic-enzyme products from Eurand and Abbott Laboratories.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY